Sign in

NCT06063850RecruitingPhase 1/2

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)

Source: ClinicalTrials.gov · Last updated 24 Aug 2026

Brief summary (registry, in English)

The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).

Status (registry)
Recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
12 (estimated)
First submitted
1 Sept 2023
Start date
12 Jun 2024
Primary completion date
30 Nov 2026
Lead sponsor
UniQure Biopharma B.V.
Diseases
Epilepsy
NCT number
NCT06063850

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 12
  • From 12 Jun 2024 to the primary completion date, 30 Nov 2026
  • 18 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Implanted devices that would contraindicate MRI; MRI-compatible devices must be implanted ≥3 months prior to Screening (vagus nerve stimulation devices will be up to discretion of the Investigator).
  • Any other contraindications to general anesthesia, surgery, or intra-operative magnetic resonance imaging (MRI).
  • Previous major disease-unrelated neurosurgical intervention due to intracranial tumor, trauma, or bleeding and/or history of previous intracranial surgery for treatment of epileptic seizures, not including diagnostic stereo-EEG.
  • Status epilepticus within the year prior to Screening.

Other illness

  • Bilateral or multifocal epilepsy; or inability to confidently lateralize seizure onset.
  • Dementia or other progressive neurological disorders and progressive brain lesions.

Lab values

  • Medications that could confound clinical (e.g., antipsychotic medication and anti-viral therapy) and laboratory evaluations or could affect a participant's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule.

Other

  • MRI evidence of epileptogenic, extra-temporal lesions, or dual temporal lobe pathology.

Who the study is looking for

  • Diagnosis of unilateral refractory MTLE
  • History of seizures with an average of ≥ 2 documented focal impaired awareness seizures or focal to bilateral tonic-clonic seizures per 30-day period over the 3 month Retrospective Period.
  • On a stable type and dose regimen of up to a maximum of 4 approved Anti Seizure Drugs for at least 1 month prior to the Retrospective Period.
  • Confirmed unilateral hippocampal pathology and concordant unilateral seizure focus
  • No evidence of focal neurocognitive dysfunction, inconsistent with disease pathology- related MRI and/or (18F)FDG-PET findings.
  • Women of childbearing potential (WOCBP) and fertile male subjects must be willing and able to use highly effective methods of birth control consistently and correctly throughout the study.
  • For WOCBP only: Negative pregnancy test.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (18)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Baylor Scott & White Medical Center
Coordinator of this site? Confirm its status
AustinUnited StatesRecruiting
Johns Hopkins School of Medicine
Coordinator of this site? Confirm its status
BaltimoreUnited StatesRecruiting
Midatlantic Epilepsy and Sleep Center
Coordinator of this site? Confirm its status
BethesdaUnited StatesCompleted
University of Alabama at Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited StatesRecruiting
Massachusetts General Hospital
Coordinator of this site? Confirm its status
BostonUnited StatesRecruiting
Cleveland Clinic
Coordinator of this site? Confirm its status
ClevelandUnited StatesRecruiting
Ohio State University
Coordinator of this site? Confirm its status
ColumbusUnited StatesRecruiting
Corewell Health
Coordinator of this site? Confirm its status
Grand RapidsUnited StatesRecruiting
Northeast Regional Epilepsy Group
Coordinator of this site? Confirm its status
HackensackUnited StatesRecruiting
Mayo Clinic Florida
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesRecruiting
Kansas University Medical Center
Coordinator of this site? Confirm its status
Kansas CityUnited StatesRecruiting
Dartmouth Hitchcock Medical Center
Coordinator of this site? Confirm its status
LebanonUnited StatesRecruiting
Medical College of Wisconsin
Coordinator of this site? Confirm its status
MilwaukeeUnited StatesRecruiting
Robert Wood Johnson Hospital
Coordinator of this site? Confirm its status
New BrunswickUnited StatesRecruiting
Stanford University
Coordinator of this site? Confirm its status
Palo AltoUnited StatesCompleted
Hospital of the University of Pennsylvania
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting
Mayo Clinic - Arizona
Coordinator of this site? Confirm its status
PhoenixUnited StatesRecruiting
Allegheny Health Network
Coordinator of this site? Confirm its status
PittsburghUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.